Apidra (insulin glulisine injection) is a fast-action, parenteral blood glucose reduction drug used to lower blood sugar levels in adults with diabetes mellitus. This drug works to curb hyperglycemia, notes the National Institutes of Health. Apidra is taken 15 minutes before a meal or up to 20 minutes after beginning to eat. Apidra is injected; dosage is determine by the doctor after determining patient needs.
Hypoglycemia
Hypoglycemia, low blood sugar, may occur in patients using Apidra. A patient may experience hypoglycemia and move into an unconscious state if drug dosage levels are not properly calculated, if food intake is not sufficient, or if unusual stress occurs. Hypoglycemia is a very dangerous condition. Patients on Apidra will be instructed to monitor blood sugars on a consistent schedule.
Allergy
A localized allergic reaction may occur at the injection site with Apidra use. The skin may itch, turn red or get swollen. The localized reaction is usually of short duration. A systemic allergy may also occur. This may cause trouble breathing, drop in blood pressure, wheezing and potentially fatal anaphylactic reactions, notes the National Institutes of Health.
Renal Problems
Renal disorders may occur while on treatment with Apidra. Treatment dosages will be adjusted if this problem arises.
Nasopharyngitis
Nasopharyngitis may arise during Apidra treatment. Nasopharyngitis involves inflammation of the upper pharynx and and nasal passages in the nose. The nose may become stuffy and the pharynx may feel irritated during treatment with Apidra. Upper respiratory tract infections may be problematic during this drug treatment for diabetes.
Hypokalemia
Hypokalemia may occur with Apidra use. This disorder will require immediate treatment to prevent life threatening disorders including respiratory and cardiac problems. Potassium levels will be monitored while patients undergo treatment with Apidra to ensure that hypokalemia does not develop.
Member Comments